Nasdaq

Shuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical Trial

Shuttle Pharmaceuticals raised approximately $5.75 million through a public offering to fund its Phase II clinical trial and operations. Shuttle Pharmaceuticals Holdings, Inc. announced the closing of ...
Nasdaq

Shuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual Update

Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update following the filing of its Annual Report, highlighting significant advancements in its cancer treatment initiatives. The company ...
Investing

Shuttle Inc (2405)

Determining whether Shuttle Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Shuttle Inc ...
Barron's

Shuttle Pharmaceuticals Holdings Inc.

About Shuttle Pharmaceuticals Holdings Inc. Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also ...